Honokiol for ALS
Also known as: Magnolia bark extract
Honokiol's BBB/BSCB penetrance and SIRT3 activation make it a unique candidate for ALS mitochondrial rescue.
Mechanism of Action
Honokiol crosses the blood-spinal-cord barrier, activating SIRT3 in motor neurons to enhance SOD2-dependent antioxidant defense and mitochondrial function. It reduces NF-κB-mediated neuroinflammation and inhibits glutamate excitotoxicity.
General mechanism: Biphenol from magnolia bark. SIRT3 activator, NF-κB/STAT3 inhibitor, mTOR suppressor. Crosses BBB/BSCB.
Current Evidence
Preclinical neuroprotection evidence. BBB/BSCB penetrance is a significant advantage over many natural compounds. No ALS trials.
Clinical Status: Preclinical. Unique BBB/BSCB penetrance among natural compounds.
Safety Profile
Safe in preclinical studies. Long history of use in traditional medicine. Mild sedative effects. Limited human safety data at therapeutic doses.
Key Research Questions
- Can honokiol reach motor neurons in the spinal cord at therapeutic levels?
- Does SIRT3 activation protect motor neurons from ALS mitochondrial dysfunction?